Physician profile

James Dittman

Richmond, VA

NPI 1881343176

$1,561.38

in general payments reported to CMS, 2019-2025

5 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$1,108.41
Education$187.33

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Medtronic, INC. $812.98 2022-2023 Endurant Iis, Abre
Silk Road Medical, INC. $267.85 2022-2023 Enroute Transcarotid Neuroprotection System, Enroute Transcarotid Stent
Shockwave Medical, INC $224.43 2024 Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter
Bolton Medical INC $148.43 2023 Relay Thoracic Stent-Graft With Plus Delivery System
Medical Device Business Services, INC. $107.69 2024

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

James Dittman

$1,561.38

in general payments reported 2019-2025

Years
2022-2024
Top company
Medtronic, INC.

https://glasscript.com/doctor/11422092/james-dittman

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.